In vitro activity of miltefosine as a single agent and in combination with voriconazole or posaconazole against uncommon filamentous fungal pathogens

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 12, 2013, Pages 2842-2846

  Biswas, Chayanika ^a   Sorrell, Tania C ^a,b   Djordjevic, Julianne T ^a   Zuo, Xiaoming ^a   Jolliffe, Katrina A ^c   Chen, Sharon C A ^a,b,d  

^a WESTMEAD HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d WESTMEAD HOSPITAL   (Australia)

Author keywords

Mucormycetes; Susceptibility; Synergy

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; ITRACONAZOLE; MILTEFOSINE; POSACONAZOLE; VORICONAZOLE;

ABSIDIA; ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS; ASPERGILLUS FUMIGATUS; BROTH DILUTION; CONTROLLED STUDY; DRUG POTENTIATION; FUNGUS ISOLATION; FUSARIUM OXYSPORUM; FUSARIUM SOLANI; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MUCOR CIRCINELLOIDES; MUCOR INDICUS; MUCOR RACEMOSUS; MUCOR RAMOSISSIMUS; NONHUMAN; RHIZOMUCOR; RHIZOPUS MICROSPORUS; RHIZOPUS ORYZAE; SCEDOSPORIUM; SCEDOSPORIUM APIOSPERMUM; SCEDOSPORIUM PROLIFICANS;

MUCORMYCETES; SUSCEPTIBILITY; SYNERGY;

ANTIFUNGAL AGENTS; DRUG SYNERGISM; FUNGI; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOSES; PHOSPHORYLCHOLINE; PYRIMIDINES; TRIAZOLES;

EID: 84887555572     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt282     Document Type: Article

References (21)

1. Pfaller MA, Diekema DJ. Epidemiology of invasive mycoses in North America. Crit Rev Microbiol 2010; 36: 1-53.
2. Fohrer C, Fornecker L, Nivoix Y et al. Antifungal combination treatment: a future perspective. Int J Antimicrob Agents 2006; 27 Suppl 1: 25-30.
3. Reed C, Bryant R, Ibrahim AS et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis 2008; 47: 364-71.
4. Spellberg B, Ibrahim A, Roilides E et al. Combination therapy for mucormycosis: why, what, and how? Clin Infect Dis 2012; 54 Suppl 1: S73-8.
5. Widmer F, Wright LC, Obando D et al. Hexadecylphosphocholine (miltefosine) has broad-spectrum fungicidal activity and is efficacious in a mouse model of cryptococcosis. Antimicrob Agents Chemother 2006; 50: 414-21.
6. Quan C, Spellberg B. Mucormycosis, pseudallescheriasis, and other uncommon mold infections. Proc Am Thorac Soc 2010; 7: 210-5.
7. Troke P, Aguirrebengoa K, Arteaga C et al. Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrob Agents Chemother 2008; 52: 1743-50.
8. de Hoog GS, Guarro J, Gene J et al. Atlas of Clinical Fungi.Washington, DC: American Society for Microbiology Press, 2000.
9. Ciardo DE, Lucke K, Imhof A et al. Systematic internal transcribed spacer sequence analysis for identification of clinical mold isolates in diagnostic mycology: a 5-year study. J Clin Microbiol 2010; 48: 2809-13.
10. O'Donnell K, Sutton DA, Rinaldi MG et al. Internet-accessible DNA sequence database for identifying fusaria from human and animal infections. J Clin Microbiol 2010; 48: 3708-18.
11. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi-Second Edition: Approved Standard M38-A2. CLSI,Wayne,, USA, 2008.
12. Castro C, Serrano MC, Flores B et al. Comparison of the Sensititre YeastOne colorimetric antifungal panel with a modified NCCLS M38-A method to determine the activity of voriconazole against clinical isolates of Aspergillus spp. J Clin Microbiol 2004; 42: 4358-60.
13. Hindler J. Antimicrobial susceptibility testing. In: Isenberg HD, ed. Clinical Microbiology Procedures Handbook. Washington, DC: American Society for Microbiology Press, 1995; 5.18.11-20.
14. Drogari-Apiranthitou M, Mantopoulou FD, Skiada A et al. In vitro antifungal susceptibility of filamentous fungi causing rare infections: synergy testing of amphotericin B, posaconazole and anidulafungin in pairs. J Antimicrob Chemother 2012; 67: 1937-40.
15. Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev 2007; 20: 695-704.
16. Howden BP, Slavin MA, Schwarer AP et al. Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine. Eur J Clin Microbiol Infect Dis 2003; 22: 111-3.
17. Kesson AM, Bellemore MC, O'Mara TJ et al. Scedosporium prolificans osteomyelitis in an immunocompetent child treated with a novel agent, hexadecylphosphocholine (miltefosine), in combination with terbinafine and voriconazole: a case report. Clin Infect Dis 2009; 48: 1257-61.
18. Wiederhold NP, Najvar LK, Bocanegra R et al. Limited activity of miltefosine in murine models of cryptococcal meningoencephalitis and disseminated cryptococcosis. Antimicrob Agents Chemother 2013; 57: 745-50.
19. Greer ND. Posaconazole (Noxafil): a new triazole antifungal agent. Proc (Bayl Univ Med Cent) 2007; 20: 188-96.
20. Paiva JA, Pereira JM. New antifungal antibiotics. Curr Opin Infect Dis 2013; 26: 168-74.
21. Zuo X, Djordjevic JT, Bijosono Oei J et al. Miltefosine induces apoptosis-like cell death in yeast via Cox9p in cytochrome c oxidase. Mol Pharmacol 2011; 80: 476-85.